10-K: TherapeuticsMD Navigates Royalty Model Amid Legal Battles

TherapeuticsMD reports reduced net loss and increased license revenue in 2025, but faces substantial doubt about its going concern status due to ongoing legal disputes and liquidity challenges.

Summary

• TherapeuticsMD transitioned from a women's healthcare company to a pharmaceutical royalty company in December 2022, licensing products like IMVEXXY, BIJUVA, ANNOVERA, and prescription prenatal vitamins.
• License revenue increased by 71.6% to $3.022 million in 2025 from $1.761 million in 2024, primarily from the Mayne License Agreement.
• The company reported a net loss of $0.569 million in 2025, a significant improvement from a $2.181 million net loss in 2024.
• Loss from continuing operations decreased by 28.2% to $4.390 million in 2025 from $6.112 million in 2024, reflecting increased sales from licensed products and operational efficiencies.
• Cash and cash equivalents increased to $7.483 million as of December 31, 2025, from $5.059 million in 2024.
• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months, contingent on royalty payments, resolution of legal disputes, and expense minimization.
• TherapeuticsMD is engaged in ongoing lawsuits with Mayne Pharma regarding net working capital allowances, with a magistrate judge recommending partial dismissal and a stay for dispute resolution.
• Patent infringement lawsuits are ongoing against Teva Pharmaceuticals and Sun Pharma Inc. concerning generic versions of IMVEXXY, with Mayne Pharma responsible for enforcement and costs.
• The company operates with one full-time employee (CEO Marlan D. Walker) and external consultants for financial, IT, legal, and regulatory matters.
• Authorized common stock shares were increased from 32 million to 640 million, effective January 5, 2026, following stockholder approval on December 15, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the significant reduction in net loss and strong growth in license revenue are positive, the 'going concern' warning and ongoing, complex legal disputes introduce substantial uncertainty and risk to the company's long-term viability.

Positives

• License revenue significantly increased by 71.6% to $3.022 million in 2025, up from $1.761 million in 2024.
• Net loss improved substantially, decreasing to $0.569 million in 2025 from $2.181 million in 2024.
• Loss from operations decreased by 28.2% to $4.390 million in 2025, indicating improved operational efficiency as a royalty-based business.
• Cash and cash equivalents increased by $2.424 million, reaching $7.483 million by December 31, 2025.
• Sublease income increased to $1.847 million in 2025 from $1.352 million in 2024, partially offsetting other income decreases.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months.
• Ongoing legal disputes with Mayne Pharma regarding net working capital allowances could materially adversely affect revenue, results of operations, and financial condition.
• Patent infringement lawsuits against Teva and Sun Pharma for generic IMVEXXY pose a risk of early loss of exclusivity (LOE), which would reduce royalty rates to 2.0% from 8.0% (or 7.5%).
• The company's business model is entirely dependent on third-party licensees' sales and commercialization efforts, introducing significant reliance risk.
• Stockholders' equity decreased to $26.876 million in 2025 from $27.370 million in 2024.
• General and administrative expenses increased by 12.4% to $6.852 million in 2025, primarily due to higher bonus expense and investor relations costs.

Risks

• All revenue is derived from royalties, and failure of licensees to maintain or increase sales could adversely affect business, financial condition, and growth.
• Incurred net losses in the past and may not maintain or increase profitability in the future, potentially leading to business discontinuation or unfavorable transactions if additional financing is not secured.
• Substantial doubt about the ability to continue as a going concern due to current liquidity, dependence on royalty payments, resolution of Mayne Lawsuits, and ability to minimize operating expenses.
• Dependence on third parties for manufacturing and supply of products may cause delays or prevent successful commercialization by licensees.
• Commercial success depends on gaining and retaining significant market acceptance among physicians and payers, which is subject to competition, pricing, and regulatory factors.
• Coverage and reimbursement may not be available for products, making it difficult for licensees to sell profitably.
• Ongoing disputes with Mayne Pharma could result in significant damages, indemnification obligations, or offsets against future royalty payments.
• Time and costs associated with winding down historical business operations may be significant, including potential litigation and unforeseen liabilities.
• Significant turnover in top executives and dependence on a single CEO (Marlan D. Walker) could adversely affect business and operations.
• Subleasing properties could expose the company to liabilities and losses if subtenants default or if properties cannot be subleased on favorable terms.
• Licensing of intellectual property involves complex legal, business, and scientific issues, and disputes could jeopardize rights under agreements.
• Reliance on Mayne Pharma to prosecute, file lawsuits, or take other actions to protect or enforce intellectual property, with no guarantee of their success or willingness.
• Inadequate protection of intellectual property could allow competitors to use technologies and erode competitive advantage.
• Significant competition from branded and generic products could adversely affect operating results and royalty revenues.
• Success is tied to licensees' distribution channels; refusal by customers or inability to replace them would harm business.
• Failure to attract and retain qualified personnel (currently one employee and external consultants) could negatively impact business operations.
• Future pandemics or epidemics could negatively affect licensees' sales efforts, supply chains, and demand for products.
• Failure to obtain regulatory approval outside the U.S. will prevent licensees from marketing products in non-U.S. markets.
• Ability to utilize net operating loss carryforwards may be limited by Section 382 ownership changes and the 80% deduction limit under the CARES Act.
• Failure of licensees to adequately maintain a sales force or promote products will impede growth.
• Risk of being treated as a public shell company, potentially leading to Nasdaq delisting and reduced liquidity/market price of common stock.
• Principal stockholder (Rubric Capital Management LP) owns a significant percentage (25.5%) and can exert significant control over stockholder approval matters.
• Failure to maintain proper internal controls could impair ability to produce accurate financial statements or comply with regulations.
• No current intention to pay dividends, limiting returns to stock value appreciation.
• Provisions in charter documents and Nevada law may have anti-takeover effects.
• Unfavorable publicity or lack of consumer acceptance could harm business.
• Product recalls, withdrawals, or regulatory enforcement actions against licensees could negatively affect business.
• Product liability lawsuits could divert resources, result in substantial liabilities, and reduce commercial potential.
• Failure to maintain optimal inventory levels by licensees could harm reputation and lead to financial losses.
• New or changing tax laws or regulations could adversely affect business.
• Failure to maintain effective and efficient information systems or properly safeguard information systems, including cybersecurity threats, could disrupt business and lead to liabilities.
• Failure to comply with foreign data protection laws and regulations (e.g., GDPR) could lead to government enforcement actions and significant penalties.
• Employees and business partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and insider trading.
• Litigation for infringing intellectual property rights of third parties would be costly and time-consuming.
• Inability to protect the confidentiality of certain unpatented information (trade secrets, know-how) could adversely affect product and technology value.
• If the continued exploration of strategic alternatives is unsuccessful, financial condition and results of operations may be materially adversely affected.
• Claims that former employees wrongfully used or disclosed alleged trade secrets of former employers could lead to litigation and material costs.

Future Outlook

The company's ability to fund operations for the next twelve months is dependent on continued royalty payments, favorable resolution of the Mayne Lawsuits, and effective minimization of operating expenses. There is a risk that existing cash reserves may be insufficient if Mayne Pharma's sales grow slower than expected, if the net working capital settlement is greater than current estimates, if the Mayne Lawsuits' outcome is unfavorable, or if future financings are unsuccessful. The company may need to raise additional capital through equity or debt financing, which could dilute existing stockholders. The outcome of ongoing patent infringement lawsuits against generic competitors for IMVEXXY could significantly impact future royalty revenues.

Management Comments

• "We continue to believe our estimated allowances for payer rebates and wholesale distributor fees are reasonable."
• "Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material."
• "We believe that corrective actions to address the compliance issues identified in the referenced Forms 483 have been implemented by the CMOs and that the CMOs continue to have the right to manufacture under current regulations."
• "We believe our patents and trademarks are valuable and provide us certain benefits in marketing our products."
• "We intend to actively protect our intellectual property with patents, trademarks, trade secrets, or other legal avenues for the protection of intellectual property and to aggressively prosecute, enforce, and defend our patents, trademarks, and proprietary technology, including those licensed by Mayne Pharma, Knight and Theramex, with our licensees to the extent permitted under their respective license agreements."
• "We have incurred and recorded legal costs amounting to $2,334 thousand in prepaid expenses and other current assets as of December 31, 2025, for the IMVEXXY Paragraph IV legal proceeding since we believe that we will successfully prevail in this legal proceeding."

Industry Context

StockSavvy.ai notes that TherapeuticsMD's transition to a pure pharmaceutical royalty model aligns with a broader industry trend where smaller biotech or specialty pharma companies monetize their intellectual property through licensing to larger commercial entities. This strategy reduces operational overhead (R&D, manufacturing, sales force) but introduces significant dependence on licensee performance and intellectual property protection. The ongoing patent challenges from generic manufacturers like Teva and Sun Pharma for IMVEXXY highlight the intense competitive pressures and legal complexities inherent in the pharmaceutical sector, particularly for branded products nearing patent expiration. The impact of the Inflation Reduction Act (IRA) on drug pricing and rebates is a critical industry-wide concern that could affect royalty streams for all pharmaceutical royalty companies.

Comparison to Industry Standards

• The company's net loss of $0.569 million in 2025, while an improvement, is still a loss, which is not uncommon for smaller pharmaceutical royalty companies that have recently divested commercial operations and are in a transition phase. However, the 'going concern' warning is a significant red flag that differentiates it from more stable, profitable royalty firms.
• The 71.6% increase in license revenue is a positive indicator of initial success in the royalty model, but the absolute revenue figure of $3.022 million is relatively modest compared to established pharmaceutical companies with diverse royalty portfolios.
• The royalty rates of 8.0% (first $80M) and 7.5% (above $80M) from Mayne Pharma are within the typical range for licensed pharmaceutical products, but the potential reduction to 2.0% upon generic launch is a standard industry risk.
• The ongoing patent litigation against Teva and Sun Pharma for IMVEXXY, with patents expiring in 2032/2033, is a common scenario in the pharmaceutical industry as generic companies seek to enter the market before patent expiry. The outcome of such cases can significantly impact future revenue streams, similar to how other branded drug companies like Pfizer or Merck defend their key patents.
• The company's reliance on a single CEO and a limited number of consultants for operations is a lean model, but it presents a higher key-personnel risk compared to larger, more diversified pharmaceutical or royalty companies with extensive management teams.

Management Changes

Corporate Governance

Legal Proceedings

• **Mayne Lawsuit (TherapeuticsMD vs. Mayne Pharma)**: Filed April 8, 2025, seeking damages for breach of contract, implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to net working capital allowances. An amended complaint was filed June 20, 2025. A magistrate judge recommended partial dismissal of claims (breach of good faith, certain breach of contract, fraudulent inducement with leave to amend) and denial of dismissal for other claims on March 23, 2026. The judge also recommended staying the lawsuit for net working capital claims to go to dispute resolution.
• **Mayne Countersuit (Mayne Pharma vs. TherapeuticsMD)**: Filed May 30, 2025, seeking damages for breach of contract and fraudulent inducement, and making indemnification demands. A magistrate judge recommended granting TherapeuticsMD's motion to dismiss the fraudulent inducement claim but denying dismissal of other claims on March 23, 2026.
• **IMVEXXY Patent Litigation (Teva Pharmaceuticals)**: Received Paragraph IV certification notice letter in February 2020 from Teva regarding an ANDA for a generic IMVEXXY. TherapeuticsMD filed a patent infringement complaint in April 2020. The statutory 30-month stay was extended and then lifted in November 2024. Litigation is ongoing and has progressed to claim construction. TherapeuticsMD has capitalized $2,334 thousand in legal costs for this proceeding.
• **IMVEXXY Patent Litigation (Sun Pharma Inc.)**: Mayne Pharma received a Paragraph IV certification notice letter in June 2024 from Sun Pharma regarding an ANDA for a generic IMVEXXY. TherapeuticsMD and Mayne Pharma filed a patent infringement complaint in July 2024. Litigation is ongoing and has progressed to claim construction.
• Mayne Pharma is responsible for the enforcement and costs of the patent litigation related to Teva and Sun Pharma under the Mayne License Agreement.

Related Party Transactions

• **Rubric Capital Management LP**: As of March 23, 2026, Rubric and its affiliates beneficially owned approximately 25.5% of common stock. Justin Roberts, a Partner at Rubric, serves as a director but has elected not to receive compensation for his service.
• **Subscription Agreement with Rubric**: On May 1, 2023, the company entered into an agreement to sell up to 5,000,000 shares of common stock to Rubric for up to $5,000,000. $1.15 million in gross proceeds was received from a drawdown on June 29, 2023, and $2.0 million from another drawdown on November 15, 2023. No drawdowns occurred in 2024 and 2025.
• **Redemption of Series A Preferred Stock**: On December 30, 2022, the company redeemed all 29,000 outstanding shares of Series A Preferred Stock from Rubric affiliates at $1,333 per share, and paid approximately $3.0 million as a make-whole payment.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future capital raises and significant uncertainty due to the 'going concern' warning and ongoing legal disputes. The stock price is likely to remain volatile. Rubric Capital Management LP, as a major shareholder, has significant influence.
• **Licensees (Mayne Pharma, Knight, Theramex)**: Their commercial success directly impacts TherapeuticsMD's royalty revenues. The Mayne Lawsuits could strain the relationship and affect cooperation, potentially impacting product commercialization and intellectual property enforcement.
• **Employees**: The company currently has only one full-time employee (CEO), making it highly dependent on this individual and external consultants. This lean structure reduces overhead but increases key-personnel risk.
• **Creditors**: The 'going concern' warning indicates increased risk for creditors, as the company's ability to meet its financial obligations is uncertain without additional financing or favorable legal outcomes.
• **Customers/Patients (of licensed products)**: While TherapeuticsMD no longer directly commercializes products, regulatory actions or supply chain disruptions affecting licensed products (IMVEXXY, BIJUVA, ANNOVERA) could impact product availability and patient access, though this is primarily managed by licensees.

Next Steps

• Resolve the Mayne Lawsuits, potentially through a dispute resolution process for net working capital claims.
• Continue to defend against patent infringement lawsuits from Teva Pharmaceuticals and Sun Pharma Inc. for IMVEXXY.
• Monitor Mayne Pharma's sales of licensed products and the net working capital settlement.
• Evaluate and potentially pursue equity and debt financing alternatives to address liquidity needs.
• Continue to wind down historical business operations and manage associated costs and liabilities.
• Monitor the impact of new healthcare legislation and regulations, such as the Inflation Reduction Act, on royalty revenues.

Key Dates

Recommendation

TherapeuticsMD presents a mixed bag of improved financial performance (reduced net loss, increased license revenue) and significant risks, most notably the 'going concern' warning and ongoing, complex legal battles with its primary licensee and generic competitors. While the company has successfully transitioned to a royalty model and shown some operational efficiencies, the substantial doubt about its ability to continue as a going concern, coupled with the uncertainty of the Mayne Lawsuits and patent infringement cases, creates a highly speculative investment environment. The potential for significant dilution from future capital raises and the heavy reliance on a single CEO further complicate the outlook. A 'hold' recommendation is appropriate for existing investors who are comfortable with high risk and awaiting clarity on the legal outcomes and long-term liquidity, but new investors should exercise extreme caution due to the inherent uncertainties.

Keywords

Pharmaceutical Royalty Company, SEC 10-K, TherapeuticsMD, TXMD, IMVEXXY, BIJUVA, ANNOVERA, Mayne Pharma, Patent Litigation, Generic Drugs, Going Concern, License Revenue, Women's Healthcare, Hormone Therapy, Contraceptive, Net Operating Loss, Corporate Governance, Cybersecurity, Rubric Capital Management